A leadership flux and the consequent tinkering in corporate strategy has taken a toll on this one-time pharma bellwether.

As valuation looks comfortable, market experts believe it is a good time to enter the market at current valuation and reap the benefits of ...

In FY16, the top five — Sun Pharma, Dr Reddy’s, Lupin, Aurobindo and Cipla — ran up a total bill of Rs 3,497 crore in legal and professiona...

The US business is 20% of total revenues. As the proportion of this high-margin business grows, it will help Cipla improve profitability.

For investors looking at value buys of quality stocks from a longer term perspective – Cipla may just be the right pick at this juncture.

The S&P BSE Sensex recouped losses after falling as much as 133 points in opening trade on Wednesday following muted trend seen in other As...

Indian markets are expected to trade in a range. Here is a list of twelve stocks which are likely to remain in focus today.

Acquisitions of two companies in the US will help Cipla increase its foothold in the market and has made analysts bullish on the counter.

We have had a good beginning in the US since our ‘go live’ in January 2015 and we expect to continue our growth trajectory there.

Cipla on Friday fulfilled a longstanding desire to expand its beachhead in the US by buying Hetero Pharma’s US business for about $550 mill...